Testing a new immune medicine for advanced or metastatic solid tumors
Part of Cancer clinical trials.
This early-phase trial tests NB002, a new immune-targeting medicine, to find safe doses and see how well it can treat advanced or metastatic solid cancers that have not responded to standard treatments. It may help by strengthening the immune system’s ability to fight the tumor.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are age 18 or older and can sign informed consent.
- You have advanced, recurring, and/or metastatic solid cancer that has not responded to standard therapy (or there is no suitable option).
- Your cancer has measurable disease for the dose expansion part (and at least evaluable disease for the dose-escalation part).
- Your overall health is good enough (ECOG 0–1) and you have at least 3 months of expected life.
- Your blood, liver, and kidney tests are at safe levels (including certain minimum white blood cell, platelet, hemoglobin, and kidney function thresholds).
- If you are pregnant or breastfeeding, you cannot join; if you can become pregnant, you must use highly effective birth control and pass required pregnancy tests.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called BT02 for people with advanced solid tumors who have not had any cancer treatment before. It aims to see if BT02 is safe and how well it works.
This early-phase trial tests a new oral targeted drug, ND-003, for people with advanced solid tumors that have not responded to standard therapy. The study focuses on tumors with specific gene changes (NTRK or RET fusions), especially in the second part, to see if the drug can shrink tumors and be safe.
This trial tests an experimental drug called IPN01203 for people with advanced solid tumors that have grown after prior immunotherapy. The goal is to see if the drug is safe and can shrink tumors.
This trial tests a new drug called DNP002 for people with advanced solid tumors that have stopped responding to standard treatments. It aims to see if DNP002 is safe and can help shrink tumors or slow their growth.
This trial tests an experimental drug for people with advanced solid tumors, including small cell lung cancer, that have stopped responding to standard treatments. The goal is to find out if the drug is safe and effective.
This early-phase trial tests a new drug (CD-001) for people with advanced solid tumors. It will check if the drug is safe, how the body handles it, and if it helps shrink tumors.
Hear when a new Advanced Solid Tumor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.